Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide and Abemaciclib in High-Risk Prostate Cancer
NCT05617885Phase 1Terminated
- Start
- Aug 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abemaciclib in prostate cancer (PCa) (3 arms). Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 2 more. Started Aug 2023; status: terminated.
02
Drugs
abemaciclib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05617885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05617885.